Prof G Markets EV Tax Credit Comes to an End & Why Trump Rx Will Not Fix High Drug Costs
236 snips
Oct 2, 2025 
Jon McNeill, former president of Tesla and current CEO of DVX Ventures, discusses the implications of the EV tax credit's expiration for prices and market demand. He shares insights on the global EV landscape, including the competitive pressures from China. Joining him, Courtney Breen from Bernstein Research analyzes the TrumpRx initiative, revealing why it may not effectively tackle high drug prices. They delve into who benefits from the initiative and touch on dynamics in the pharmaceutical industry, emphasizing potential trade-offs for consumers and companies alike.
AI Snips
Chapters
Transcript
Episode notes
Push Cost Cuts To Compete
- Automakers should keep reducing battery and production costs to stay competitive without subsidies.
- McNeill notes GM's multi-generation battery improvements and scale help compete globally.
China's Industrial Playbook Matters
- Chinese EV makers like BYD benefit from subsidized capacity and aggressive export expansion.
- McNeill warns the U.S. industry must learn efficiencies and aim to offer $20k–$25k competitive EVs.
Darwinian Strategy Behind Chinese Winners
- China fosters many players, lets winners emerge, then consolidates capacity under those winners for export dominance.
- McNeill sees BYD and others expanding globally with local factories and supply chains.